Paragraph IV Certification Notice, Month Stay Period

No definition available.

Name:	amag_ParagraphIVCertificationNoticeMonthStayPeriod
Namespace Prefix:	amag_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the period of time in during which a patent infringement suit can be filed in federal district court after receipt of the Paragraph IV certification.

+ References

No definition available.

+ Details

Name:	amag_ParagraphIvCertificationNoticeTimePeriodDuringWhichPatentInfringementSuitCanBeFiled
Namespace Prefix:	amag_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and Development Asset Acquired Other Than Through Business Combination, Future Contingent Payments

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFutureContingentPayments
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research And Development Asset Acquired Other Than Through Business Combination, Royalty Percentage

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationRoyaltyPercentage
Namespace Prefix:	amag_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Research And Development Asset Acquired Other Than Through Business Combination, Threshold For Future Contingent Payments

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationThresholdForFutureContingentPayments
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research And Development Asset Acquired Other than Through Business Combination, Period After Sale

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherthanThroughBusinessCombinationPeriodAfterSale
Namespace Prefix:	amag_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and Development Asset Acquired Other Than Through Business Combination, Sales Milestone

+ References

No definition available.

+ Details

Name:	amag_ResearchandDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationSalesMilestone
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research and Development Asset Acquired Other Than Through Business Combination, Sales Milestone Threshold

+ References

No definition available.

+ Details

Name:	amag_ResearchandDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationSalesMilestoneThreshold
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=amag_SandozPatentInfringementLawsuitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=amag_EndoceuticsLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=amag_PalatinLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_EndoceuticsLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByLiabilityClassAxis=amag_ContingentConsiderationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationFirstSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=amag_EndoceuticsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationSecondSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationThirdSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationTieredRoyaltiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationRegulatoryMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationRegulatoryMilestoneAchievementAcceptanceByU.S.FoodAndDrugAdministrationForNewDrugApplicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationRegulatoryMilestoneAchievementU.S.FoodAndDrugAdministrationApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) - USD ($)			1 Months Ended	9 Months Ended
Commitments and Contingencies (Details) - USD ($)	Apr. 03, 2017	Feb. 05, 2016	Mar. 31, 2016	Sep. 30, 2017	Feb. 28, 2017	Dec. 31, 2016
Commitments
Contingent consideration accrued				$ 190,457,000		$ 156,008,000
Sandoz Patent Infringement Lawsuit
Commitments
Period of time, patent infringement suit can be filed in federal district court		45 days
Month stay period		30 months	30 months
Endoceutics License Agreement
Commitments
Period after first commercial sale	10 years			10 years
Palatin License Agreement \| License Agreement Terms
Commitments
Maximum future contingent payments				$ 380,000,000.0
Endoceutics License Agreement \| Contingent Consideration
Commitments
Contingent consideration accrued				10,000,000
First Sales Milestone \| Endoceutics License Agreement \| Endoceutics, Inc.
Commitments
Sales milestone	$ 15,000,000.0			15,000,000.0
Sales milestone, triggering amount	150,000,000.0			150,000,000.0
First Sales Milestone \| Palatin License Agreement \| License Agreement Terms
Commitments
Sales milestone					$ 25,000,000.0
Sales milestone, triggering amount					250,000,000.0
Maximum future contingent payments					300,000,000.0
Second Sales Milestone \| Endoceutics License Agreement \| Endoceutics, Inc.
Commitments
Sales milestone	30,000,000.0			30,000,000.0
Sales milestone, triggering amount	300,000,000.0			300,000,000.0
Third Sales Milestone \| Endoceutics License Agreement \| Endoceutics, Inc.
Commitments
Sales milestone	850,000,000.0			850,000,000.0
Sales milestone, triggering amount	500,000,000.0			500,000,000.0
Tiered Royalties \| Endoceutics License Agreement
Commitments
Maximum future contingent payments	$ 150,000,000.0			$ 150,000,000.0
Royalty percentage, maximum	20.00%			20.00%
Net sales threshold, future contingent payments	$ 1,000,000,000.0			$ 1,000,000,000.0
Regulatory milestone \| Palatin License Agreement \| License Agreement Terms
Commitments
Maximum future contingent payments					$ 80,000,000.0
Regulatory milestone, acceptance by U.S. Food and Drug Administration for new drug application \| Palatin License Agreement \| License Agreement Terms
Commitments
Maximum future contingent payments				20,000,000
Regulatory milestone, U.S. Food and Drug Administration approval \| Palatin License Agreement \| License Agreement Terms
Commitments
Maximum future contingent payments				$ 60,000,000